CCM
NVO

Copeland Capital Management’s Novo Nordisk NVO Stock Holding History

Copeland Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.83K Sell
186
-171
-48% -$8.1K ﹤0.01% 247
2025
Q4 		$18.2K Sell
357
-284
-44% -$14.5K ﹤0.01% 239
2025
Q3 		$35.6K Buy
641
+62
+11% +$3.63K ﹤0.01% 222
2025
Q2 		$40K Buy
579
+186
+47% +$12.7K ﹤0.01% 207
2025
Q1 		$27.3K Buy
393
+255
+185% +$21.1K ﹤0.01% 219
2024
Q4 		$11.9K Buy
138
+31
+29% +$3.35K ﹤0.01% 232
2024
Q3 		$12.7K Buy
+107
New +$14.3K ﹤0.01% 217
2024
Q2 		– Sell
-343
Closed -$44K – 210
2024
Q1 		$44K Buy
343
+106
+45% +$12.6K ﹤0.01% 159
2023
Q4 		$24.5K Sell
237
-45
-16% -$4.45K ﹤0.01% 198
2023
Q3 		$25.6K Hold
282
– – ﹤0.01% 196
2023
Q2 		$22.8K Hold
282
– – ﹤0.01% 199
2023
Q1 		$22K Sell
282
-64
-18% -$4.54K ﹤0.01% 202
2022
Q4 		$23K Hold
346
– – ﹤0.01% 204
2022
Q3 		$17K Hold
346
– – ﹤0.01% 209
2022
Q2 		$19K Hold
346
– – ﹤0.01% 209
2022
Q1 		$19K Sell
346
-70
-17% -$3.59K ﹤0.01% 206
2021
Q4 		$23K Sell
416
-90
-18% -$4.88K ﹤0.01% 200
2021
Q3 		$24K Hold
506
– – ﹤0.01% 197
2021
Q2 		$21K Hold
506
– – ﹤0.01% 201
2021
Q1 		$17K Hold
506
– – ﹤0.01% 208
2020
Q4 		$18K Sell
506
-1,828
-78% -$63.2K ﹤0.01% 196
2020
Q3 		$81K Sell
2,334
-536
-19% -$17.9K ﹤0.01% 140
2020
Q2 		$94K Sell
2,870
-1,760
-38% -$56.2K ﹤0.01% 138
2020
Q1 		$139K Buy
4,630
+4,124
+815% +$123K 0.01% 133
2019
Q4 		$15K Sell
506
-2,454
-83% -$68K ﹤0.01% 204
2019
Q3 		$77K Sell
2,960
-172
-5% -$4.35K ﹤0.01% 147
2019
Q2 		$80K Buy
3,132
+684
+28% +$16.9K ﹤0.01% 150
2019
Q1 		$64K Sell
2,448
-22,076
-90% -$543K ﹤0.01% 151
2018
Q4 		$565K Buy
24,524
+5,368
+28% +$119K 0.04% 120
2018
Q3 		$452K Sell
19,156
-114
-0.6% -$2.78K 0.03% 127
2018
Q2 		$444K Hold
19,270
– – 0.03% 128
2018
Q1 		$475K Buy
19,270
+510
+3% +$13.4K 0.03% 123
2017
Q4 		$503K Sell
18,760
-390
-2% -$9.92K 0.03% 131
2017
Q3 		$461K Sell
19,150
-1,498
-7% -$33.9K 0.03% 126
2017
Q2 		$443K Sell
20,648
-5,784
-22% -$117K 0.03% 120
2017
Q1 		$458K Sell
26,432
-16,292
-38% -$284K 0.03% 119
2016
Q4 		$766K Sell
42,724
-118,286
-73% -$2.14M 0.05% 124
2016
Q3 		$3.35M Buy
161,010
+29,374
+22% +$728K 0.22% 108
2016
Q2 		$3.54M Buy
131,636
+4,112
+3% +$113K 0.24% 98
2016
Q1 		$3.46M Buy
127,524
+81,774
+179% +$2.19M 0.24% 100
2015
Q4 		$1.33M Buy
45,750
+1,992
+5% +$55.1K 0.08% 131
2015
Q3 		$1.19M Sell
43,758
-132
-0.3% -$3.74K 0.07% 118
2015
Q2 		$1.2M Sell
43,890
-762,972
-95% -$21.4M 0.06% 131
2015
Q1 		$21.5M Sell
806,862
-1,890
-0.2% -$43.5K 1.43% 17
2014
Q4 		$17.1M Buy
808,752
+15,114
+2% +$338K 1.24% 38
2014
Q3 		$18.9M Buy
793,638
+75,256
+10% +$1.73M 1.92% 19
2014
Q2 		$16.6M Buy
718,382
+35,664
+5% +$787K 1.85% 19
2014
Q1 		$15.6M Sell
682,718
-60,282
-8% -$1.28M 1.9% 20
2013
Q4 		$13.7M Buy
743,000
+21,020
+3% +$366K 1.79% 29
2013
Q3 		$12.2M Buy
721,980
+69,820
+11% +$1.17M 1.9% 28
2013
Q2 		$10.1M Buy
+652,160
New +$10.9M 1.82% 38

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Copeland Capital Management's NVO Position: Q1 2026 in Review

Copeland Capital Management reduced its Novo Nordisk (NVO) stake by 48% in Q1 2026, selling an estimated $8.1K and leaving 186 shares worth $6.83K. The position accounts for ﹤0.01% of the portfolio, ranked #247.

Copeland Capital Management first reported a position in NVO in Q2 2013 and has held it in 51 quarters since. The position peaked at $21.5M in Q1 2015. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Copeland Capital Management held 186 shares of Novo Nordisk worth $6.83K as of Q1 2026.
  • Copeland Capital Management sold 171 Novo Nordisk shares in Q1 2026, an estimated $8.1K.
  • Novo Nordisk made up ﹤0.01% of Copeland Capital Management's portfolio in Q1 2026, its #247 holding.
  • Copeland Capital Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 51 quarters since.
  • Copeland Capital Management's Novo Nordisk position peaked at $21.5M in Q1 2015.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Copeland Capital Management's 13F filing for Q1 2026, filed 6 May 2026.